HYDERABAD: After AstraZeneca’s admitted in a UK courtroom that its Covid-19 vaccine triggered a rare side-effect — Thrombosis with Thrombocytopenia Syndrome (TTS), Hyderabad-based vaccine maker Bharat Biotech on Thursday burdened on the safety of its indigenous vaccine Covaxin to allay public issues over Covid vaccines.
AstraZeneca’s vaccine Vaxzevria, which it developed in collaboration with Oxford University, was manufactured underneath the Covishield brandname in India by Pune-based Serum Institute of India (SII). Bharat Biotech developed the inactivated entire virion vaccine Covaxin. Both of them had been essentially the most extensively administered vaccines underneath India’s Covid-19 vaccine immunisation drive.
Bharat Biotech stated Covaxin, which was developed with a single-minded focus on safety first, had demonstrated a wonderful safety record with none vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis or myocarditis, amongst others.”All the studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin, without any vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc,” Bharat Biotech stated in a public curiosity assertion.
Pointing out that Covaxin was the one Covid-19 vaccine within the Indian govt’s immunisation programme to have carried out efficacy trials in India, the corporate stated Covaxin was evaluated in over 27,000 topics as a part of its licensure course of and was licensed underneath restricted use in medical trial mode, the place detailed safety reporting was carried out for a number of hundred thousand topics.
Bharat Biotech additionally identified that ongoing safety monitoring was continued all through the product life cycle of Covaxin with research and safety follow-up actions demonstrating a wonderful safety record.
“As seasoned innovators and product developers, the Bharat Biotech team was well aware that, while the efficacy of Covid-19 vaccines may be short-lived, the impact on patient safety could last a lifetime. Hence safety is the primary focus for all our vaccines,” Bharat Biotech stated.
“The vaccine is developed using whole-virion inactivated vero cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead viruses, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection,” an organization spokesperson stated.
AstraZeneca’s vaccine Vaxzevria, which it developed in collaboration with Oxford University, was manufactured underneath the Covishield brandname in India by Pune-based Serum Institute of India (SII). Bharat Biotech developed the inactivated entire virion vaccine Covaxin. Both of them had been essentially the most extensively administered vaccines underneath India’s Covid-19 vaccine immunisation drive.
Bharat Biotech stated Covaxin, which was developed with a single-minded focus on safety first, had demonstrated a wonderful safety record with none vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis or myocarditis, amongst others.”All the studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin, without any vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc,” Bharat Biotech stated in a public curiosity assertion.
Pointing out that Covaxin was the one Covid-19 vaccine within the Indian govt’s immunisation programme to have carried out efficacy trials in India, the corporate stated Covaxin was evaluated in over 27,000 topics as a part of its licensure course of and was licensed underneath restricted use in medical trial mode, the place detailed safety reporting was carried out for a number of hundred thousand topics.
Bharat Biotech additionally identified that ongoing safety monitoring was continued all through the product life cycle of Covaxin with research and safety follow-up actions demonstrating a wonderful safety record.
“As seasoned innovators and product developers, the Bharat Biotech team was well aware that, while the efficacy of Covid-19 vaccines may be short-lived, the impact on patient safety could last a lifetime. Hence safety is the primary focus for all our vaccines,” Bharat Biotech stated.
“The vaccine is developed using whole-virion inactivated vero cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead viruses, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection,” an organization spokesperson stated.
